[go: up one dir, main page]

WO2011111880A9 - Pharmaceutical composition for treating or preventing diseases caused by the nuclear export of gsk3, including a compound for inhibiting the nuclear export of gsk3 - Google Patents

Pharmaceutical composition for treating or preventing diseases caused by the nuclear export of gsk3, including a compound for inhibiting the nuclear export of gsk3 Download PDF

Info

Publication number
WO2011111880A9
WO2011111880A9 PCT/KR2010/001445 KR2010001445W WO2011111880A9 WO 2011111880 A9 WO2011111880 A9 WO 2011111880A9 KR 2010001445 W KR2010001445 W KR 2010001445W WO 2011111880 A9 WO2011111880 A9 WO 2011111880A9
Authority
WO
WIPO (PCT)
Prior art keywords
gsk3
nuclear export
inhibiting
pharmaceutical composition
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2010/001445
Other languages
French (fr)
Korean (ko)
Other versions
WO2011111880A1 (en
Inventor
육종인
김현실
김남희
노경태
김수연
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioinformatics & Molecular Design Research Center
MEDIGENTEK CO Ltd
Original Assignee
Bioinformatics & Molecular Design Research Center
MEDIGENTEK CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinformatics & Molecular Design Research Center, MEDIGENTEK CO Ltd filed Critical Bioinformatics & Molecular Design Research Center
Priority to PCT/KR2010/001445 priority Critical patent/WO2011111880A1/en
Publication of WO2011111880A1 publication Critical patent/WO2011111880A1/en
Anticipated expiration legal-status Critical
Publication of WO2011111880A9 publication Critical patent/WO2011111880A9/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention relates to a pharmaceutical composition for treating or preventing disease caused by the nuclear export of GSK3, including a compound for inhibiting the nuclear export of GSK3, and more specifically, to a pharmaceutical composition for inhibiting the growth or metastasis of cancer cells and including a novel compound for inhibiting the nuclear export of GSK3, and to a pharmaceutical composition for treating autoimmune diseases. According to the present invention, a composition for inhibiting the onset and progression of a disease caused by a decrease in GSK3 concentration in a cell nucleus through the nuclear export of GSK3 is provided. The compound according to the present invention is useful for treating or preventing various diseases by inhibiting the nuclear export function of GSK3 by Axin and increasing the concentration of GSK3 in the nucleus.
PCT/KR2010/001445 2010-03-08 2010-03-08 Pharmaceutical composition for treating or preventing diseases caused by the nuclear export of gsk3, including a compound for inhibiting the nuclear export of gsk3 Ceased WO2011111880A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/KR2010/001445 WO2011111880A1 (en) 2010-03-08 2010-03-08 Pharmaceutical composition for treating or preventing diseases caused by the nuclear export of gsk3, including a compound for inhibiting the nuclear export of gsk3

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2010/001445 WO2011111880A1 (en) 2010-03-08 2010-03-08 Pharmaceutical composition for treating or preventing diseases caused by the nuclear export of gsk3, including a compound for inhibiting the nuclear export of gsk3

Publications (2)

Publication Number Publication Date
WO2011111880A1 WO2011111880A1 (en) 2011-09-15
WO2011111880A9 true WO2011111880A9 (en) 2013-01-10

Family

ID=44563667

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/001445 Ceased WO2011111880A1 (en) 2010-03-08 2010-03-08 Pharmaceutical composition for treating or preventing diseases caused by the nuclear export of gsk3, including a compound for inhibiting the nuclear export of gsk3

Country Status (1)

Country Link
WO (1) WO2011111880A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9533954B2 (en) 2010-12-22 2017-01-03 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX358640B (en) 2008-01-04 2018-08-29 Intellikine Llc Certain chemical entities, compositions and methods.
SG186989A1 (en) 2010-07-14 2013-02-28 Novartis Ag Ip receptor agonist heterocyclic compounds
TWI546305B (en) 2011-01-10 2016-08-21 英菲尼提製藥股份有限公司 Method for preparing isoquinolinone and solid form of isoquinolinone
JP6073923B2 (en) 2012-01-13 2017-02-01 ノバルティス アーゲー Condensed pyrrole as an IP receptor agonist for the treatment of pulmonary arterial hypertension (PAH) and related disorders
CA2863991C (en) * 2012-02-09 2020-08-11 Merck Patent Gmbh Tetrahydro-quinazolinone derivatives as tank and parp inhibitors
PE20190736A1 (en) 2012-06-13 2019-05-23 Incyte Holdings Corp TRICICLIC COMPOUNDS REPLACED AS INHIBITORS OF THE RECEIVER OF THE FIBROBLAST GROWTH FACTOR (FGFR)
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CN105102000B (en) 2012-11-01 2021-10-22 无限药品公司 Cancer therapy using PI3 kinase isoform modulators
US9604981B2 (en) 2013-02-13 2017-03-28 Novartis Ag IP receptor agonist heterocyclic compounds
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
KR102269032B1 (en) 2013-04-19 2021-06-24 인사이트 홀딩스 코포레이션 Bicyclic heterocycles as fgfr inhibitors
US9732065B2 (en) * 2013-05-30 2017-08-15 Sumitomo Dainippon Pharma Co., Ltd. Cyclic aminomethyl pyrimidine derivative
MX367723B (en) 2013-10-25 2019-09-03 Novartis Ag Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors.
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3200786B1 (en) 2014-10-03 2019-08-28 Novartis AG Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
ES2895769T3 (en) 2015-02-20 2022-02-22 Incyte Corp Bicyclic heterocycles as FGFR inhibitors
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
SI3788047T1 (en) 2018-05-04 2024-11-29 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
SG11202010882XA (en) 2018-05-04 2020-11-27 Incyte Corp Salts of an fgfr inhibitor
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
TW202100524A (en) * 2019-03-14 2021-01-01 愛爾蘭商健生科學愛爾蘭無限公司 Fused ring pyrimidone derivatives for use in the treatment of hbv infection or of hbv-induced diseases
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3237199A1 (en) 2021-11-02 2023-05-11 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006504755A (en) * 2002-10-15 2006-02-09 スミスクライン ビーチャム コーポレーション Pyridazine compounds as GSK-3 inhibitors
CA2575808A1 (en) * 2004-08-02 2006-02-16 Osi Pharmaceuticals, Inc. Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
JP2009531274A (en) * 2005-12-07 2009-09-03 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Kinase-inhibiting pyrrolopyridine compounds

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9533954B2 (en) 2010-12-22 2017-01-03 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors

Also Published As

Publication number Publication date
WO2011111880A1 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
WO2011111880A9 (en) Pharmaceutical composition for treating or preventing diseases caused by the nuclear export of gsk3, including a compound for inhibiting the nuclear export of gsk3
WO2010104306A3 (en) Pharmaceutical compositions for treating or preventing diseases caused by the translocation of gsk3 from the cell nucleus to the cytoplasm, containing compounds for inhibiting the translocation of gsk3 from the cell nucleus to the cytoplasm
MY160399A (en) Compounds, compositions, and methods for preventing metastasis of cancer cells
WO2013055834A3 (en) Er stress relievers in beta cell protection
WO2011085263A3 (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
WO2012177844A3 (en) Substituted imidazopyridinyl-aminopyridine compounds
WO2012109476A3 (en) Methods and compositions related to staufen 1 binding sites formed by duplexing alu elements
WO2011082270A3 (en) Substituted imidazopyridinyl-aminopyridine compounds
WO2011082266A3 (en) Substituted heterocyclic compounds
WO2012149546A3 (en) Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
MY181688A (en) Improved production of fatty acid derivatives
WO2011082267A3 (en) Substituted triazolo-pyrazine compounds
PL3321355T3 (en) Methods and compositions for the clinical recovery of allogeneic cells, and therapeutic uses
JO2939B1 (en) Tetrahydro-Pyrido-Pyrimidine Derivatives
WO2012083969A3 (en) Microrna for diagnosis of pancreatic cancer
MX2013010945A (en) Systhesis of 5-azacytidine.
WO2011160827A3 (en) Novel jnk inhibitor molecules
WO2011156794A3 (en) Synthetic pathways for biofuel synthesis
WO2012167028A9 (en) Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition
WO2011123678A3 (en) Substituted benzo-pyrido-triazolo-diazepine compounds
BR112015022529A2 (en) cell culture media and antibody production processes
WO2013034989A3 (en) Microrna-based methods and assays for osteosarcoma
EP2831234A4 (en) COMPOSITIONS, METHODS AND GENES OF PLANTS FOR BETTER PRODUCTION OF FERMENTABLE SUGARS FOR BIOFUELS PRODUCTION
WO2009101149A3 (en) Anti-tumour effective paramyxovirus
HK1210498A1 (en) Rapid method production high purity cancer stem cells and population of high purity cancer stem cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10847514

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10847514

Country of ref document: EP

Kind code of ref document: A1